Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Insider Bob D. Brown Sells 5,808 Shares


Share on StockTwits

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) insider Bob D. Brown sold 5,808 shares of the firm’s stock in a transaction on Tuesday, January 12th. The stock was sold at an average price of $24.07, for a total value of $139,798.56. Following the sale, the insider now owns 26,517 shares in the company, valued at approximately $638,264.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of DRNA traded down $0.49 during trading hours on Wednesday, hitting $23.56. The stock had a trading volume of 331,219 shares, compared to its average volume of 637,078. The firm has a market cap of $1.77 billion, a P/E ratio of -14.94 and a beta of 1.40. The company’s fifty day simple moving average is $23.37 and its 200 day simple moving average is $21.55. Dicerna Pharmaceuticals, Inc. has a 12-month low of $11.75 and a 12-month high of $27.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.12). The firm had revenue of $48.88 million during the quarter, compared to analysts’ expectations of $55.72 million. Dicerna Pharmaceuticals had a negative return on equity of 71.72% and a negative net margin of 88.81%. As a group, sell-side analysts expect that Dicerna Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in DRNA. Bank of New York Mellon Corp raised its position in Dicerna Pharmaceuticals by 15.5% in the second quarter. Bank of New York Mellon Corp now owns 289,279 shares of the biopharmaceutical company’s stock valued at $7,348,000 after purchasing an additional 38,893 shares during the period. Vanguard Group Inc. raised its position in Dicerna Pharmaceuticals by 13.0% in the second quarter. Vanguard Group Inc. now owns 3,336,975 shares of the biopharmaceutical company’s stock valued at $84,760,000 after purchasing an additional 385,118 shares during the period. Bank of America Corp DE raised its position in Dicerna Pharmaceuticals by 37.8% in the second quarter. Bank of America Corp DE now owns 216,687 shares of the biopharmaceutical company’s stock valued at $5,504,000 after purchasing an additional 59,383 shares during the period. Glenmede Trust Co. NA raised its position in Dicerna Pharmaceuticals by 32.5% in the second quarter. Glenmede Trust Co. NA now owns 9,085 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 2,230 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Dicerna Pharmaceuticals in the second quarter valued at about $1,869,000. 74.95% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on the company. B. Riley restated a “buy” rating and set a $37.00 price objective (up previously from $30.00) on shares of Dicerna Pharmaceuticals in a report on Monday. BidaskClub cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 18th. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 6th. Finally, SVB Leerink decreased their price objective on Dicerna Pharmaceuticals from $48.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, November 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $34.33.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases.

See Also: SEC Filing

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.